BPM-51545

BPM-51545 is an investigational **recombinant protein** therapeutic developed by Berg for musculoskeletal and potentially other age-related metabolic disorders. Publicly available pipeline and company materials describe it as a **biologically active recombinant enolase-1 protein** and indicate a **preclinical** development status, with activity focused on musculoskeletal disease biology and skeletal muscle research. Enolase-1 is a multifunctional glycolytic enzyme with additional signaling and plasminogen-binding biology, but the precise therapeutic mechanism, molecular target engagement model, dosing strategy, and clinical indication for BPM-51545 have not been clearly disclosed in primary public sources, so its mechanism of action should currently be regarded as incompletely characterized.

Other names

recombinant enolase-1 protein